Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23086IDB-L5

Select Item

Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat.

The Human Papillomavirus (HPV) Associated Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Human Papillomavirus (HPV) Associated Cancer
Key Targets
· Human Papillomavirus Protein E7 ; Human Papillomavirus Protein E6; Human Papillomavirus Minor Capsid Protein L2 ; Programmed Cell Death 1 Ligand 1; Human Papillomavirus Type 18 Replication Protein E1; Human herpesvirus Envelope Glycoprotein D; Ubiquitin Protein Ligase E3A; Transforming Growth Factor Beta; Human Papillomavirus Probable protein E5; and Human Papillomavirus Replication Protein E1
Key Mechanisms of Action
· Human Papillomavirus Protein E7 Inhibitor; Human Papillomavirus Protein E6 Inhibitor; Programmed Cell Death 1 Ligand 1 Inhibitor; Ubiquitin Protein Ligase E3A Inhibitor; Transforming Growth Factor Beta Inhibitor; Interleukin 2 Receptor Agonist; Interleukin 12 Receptor Agonist; Interleukin 2 Receptor Subunit Beta Agonist; Inducible T Cell Costimulator Agonist; and Interleukin 8 Inhibitor
Key Routes of Administration
· Intravenous; Intramuscular; Parenteral; Oral; Subcutaneous; Intradermal; Intratumor; Topical; Suppository; and Vaginal
Key Molecule Types
· Subunit Vaccine; Recombinant Vector Vaccine; Small Molecule; Gene-Modified Cell Therapy; Monoclonal Antibody; DNA Vaccine; mRNA Vaccine; Cell Therapy; Fusion Protein; and Vaccine
Major Companies
· German Cancer Research Center; Beijing Health Guard Biotechnology Inc; Bristol-Myers Squibb Co; Barinthus Biotherapeutics Plc; Ascendis Pharma AS; AstraZeneca Plc; Apimeds Inc; Merck KGaA; Virion Therapeutics LLC; and University of Rome Tor Vergata

Scope

  • Therapeutics in Development: Covering 111 molecules, with 92 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Human Papillomavirus (HPV) Associated Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Human Papillomavirus (HPV) Associated Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Human Papillomavirus (HPV) Associated Cancer treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

2A Pharma AB
Anison Therapeutics Oy
Anteris Technologies Ltd
Apimeds Inc
ApolloBio Corp
Ascendis Pharma AS
Astex Pharmaceuticals Inc
AstraZeneca Plc
Augusta University
Auro Vaccines LLC
Avalia Immunotherapies Ltd
Avidea Technologies Inc
Barinthus Biotherapeutics Plc
Baylor Scott & White Research Institute
Beijing Health Guard Biotechnology Inc
BioMed Valley Discoveries Inc
Biond Biologics Ltd
Blue Sky Immunotherapies GmbH
Bristol-Myers Squibb Co
Cancer Institute (WIA)
Cancer Research UK
Cellid Co Ltd
Chain Biotechnology Ltd
Chengdu Institute of Biological Products Co Ltd
Corvus Pharmaceuticals Inc
Cue Biopharma Inc
Cullinan Oncology Inc
Dragonfly Therapeutics Inc
Elicio Therapeutics Inc
eTheRNA Immunotherapies NV
Frantz Viral Therapeutics LLC
German Cancer Research Center
Gilead Sciences Inc
GSK plc
H. Lee Moffitt Cancer Center & Research Institute Inc
ImmunityBio Inc
Innovene
Inovio Pharmaceuticals Inc
ISA Pharmaceuticals BV
Jiangsu Ab&b Bio-tech Co Ltd
Kovina Therapeutics Inc
LinKinVax Europe Spas
Max Delbruck Center for Molecular Medicine
Merck & Co Inc
Merck KGaA
Myrio Therapeutics Pty Ltd
Nihon University
Novartis AG
Nutcracker Therapeutics Inc
Nykode Therapeutics ASA
OncoNano Medicine Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Pathovax LLC
Pattern Pharma Inc
PDS Biotechnology Corp
People's Hospital of Xinjiang Uygur Autonomous Region
pHion Therapeutics Ltd
Precigen Inc
Privo Technologies Inc
Rafjik Inc
RDP Pharma AG
Rottapharm Biotech Srl
Shanghai Bovax Biotechnology Co Ltd
Shuttle Pharmaceuticals Holdings Inc
Sirnaomics Ltd
Stemirna Therapeutics Ltd
Sun Yat-sen University
Symvivo Inc
TCR Cure Biopharma Technology Co Ltd
Tessa Therapeutics Ltd
Texas Biomedical Research Institute
Theravectys SA
Toragen Inc
Touchlight Genetics Ltd
Transcenta Holding Ltd
Transgene SA
UbiVac Inc
University of Arkansas
University of Oklahoma
University of Rome Tor Vergata
University of Strathclyde
Vault Pharma Inc
Vaxart Inc
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Viracta Therapeutics Inc
Virion Therapeutics LLC
Virometix AG
Vittail Ltd
VLP The Vaccines Company SL
Voltron Therapeutics Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Human Papillomavirus (HPV) Associated Cancer reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 in real time.

  • Access a live Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more